跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
CIMA-AEMPS
/
ROLTISA 5 MG CAPSULAS DURAS DE LIBERACION PROLONGADA EFG
Approved
STANDARD
ROLTISA 5 MG CAPSULAS DURAS DE LIBERACION PROLONGADA EFG
Pharmathen S.A.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Oct 14, 2022
Approval ID
1f38f778984d8d03
Company
Pharmathen S.A.
Type
Standard
Approval Details
Approval Id
1f38f778984d8d03
Drug Cima Aemps Name
ROLTISA 5 MG CAPSULAS DURAS DE LIBERACION PROLONGADA EFG
Register Number
88197
Holder Company Name
Pharmathen S.A.
Marketing Company Name
Pharmathen S.A.
Holder Company Detail Path
/organization/pharmathen-s-a
Marketing Company Detail Path
/organization/pharmathen-s-a
Authorization Date
2022-10-14
Dosage Form
CÁPSULA DURA DE LIBERACIÓN PROLONGADA
Dose
5 mg
Route Of Administration
VÍA ORAL
Prescription Type
Diagnóstico Hospitalario
Commercialized
No
Company Name
Pharmathen S.A.
Company Detail Path
/organization/pharmathen-s-a
Company Information
Pharmaceutical Company Name
PHARMATHEN S.A.
Country Name
Greece
City Name
pallini,sterea ellada and evoia,country_gr
Address
6 Dervenakion
Active Ingredients
TACROLIMUS MONOHIDRATO
5,109 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Oct 14, 2022
Approval ID
1f38f778984d8d03
Type
Standard
Back to CIMA-AEMPS Approvals
ROLTISA 5 MG CAPSULAS DURAS DE LIBERACION PROLONGADA EFG - CIMA-AEMPS Drug Approval Details